Highlights Jazz Pharmaceuticals plc

Equities

JAZZ

IE00B4Q5ZN47

Real-time Estimate Cboe BZX Other stock markets 10:13:28 2024-04-29 am EDT			5-day change	1st Jan Change
111.8 ^USD	+2.12%		+2.33%	-9.46%

Apr. 02	Jazz Pharmaceuticals Completes License Application for FDA for Biliary Tract Cancer Treatment	MT
Apr. 02	Jazz Pharmaceuticals Completes Zanidatamab Biologics License Application for Previously Treated HER2-Positive Metastatic Biliary Tract Cancer	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Jazz Pharmaceuticals Completes License Application for FDA for Biliary Tract Cancer Treatment	Apr. 02	MT
Jazz Pharmaceuticals Completes Zanidatamab Biologics License Application for Previously Treated HER2-Positive Metastatic Biliary Tract Cancer	Apr. 02	CI
Tranche Update on Jazz Pharmaceuticals plc's Equity Buyback Plan announced on November 8, 2016.	Feb. 28	CI
Jazz Pharmaceuticals Swings to Q4 Non-GAAP Earnings, Revenue Rises; 2024 Guidance Set, Shares Down After Hours	Feb. 28	MT
(JAZZ) JAZZ PHARMACEUTICALS Expects Fiscal Year 2024 EPS Range $18.15 - $19.35	Feb. 28	MT
(JAZZ) JAZZ PHARMACEUTICALS Forecasts Fiscal Year 2024 Revenue $4B-$4.2B	Feb. 28	MT
Earnings Flash (JAZZ) JAZZ PHARMACEUTICALS Reports Q4 EPS $5.02, vs. Street Est of $5.18	Feb. 28	MT
Earnings Flash (JAZZ) JAZZ PHARMACEUTICALS Posts Q4 Revenue $1.01B, vs. Street Est of $1.01B	Feb. 28	MT
Jazz Pharmaceuticals plc Provides Earnings Guidance for the Full Year 2024	Feb. 28	CI
Jazz Pharmaceuticals plc Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 28	CI
News Highlights : Top Company News of the Day - Wednesday at 5 PM ET	Feb. 21	DJ
News Highlights : Top Company News of the Day - Wednesday at 3 PM ET	Feb. 21	DJ
News Highlights : Top Company News of the Day - Wednesday at 1 PM ET	Feb. 21	DJ
News Highlights : Top Company News of the Day - Wednesday at 11 AM ET	Feb. 21	DJ
News Highlights : Top Company News of the Day - Wednesday at 9 AM ET	Feb. 21	DJ
Jazz Pharmaceuticals to Acquire Redx Pharma's KRAS Inhibitor Program	Feb. 07	MT
Barratt and Smurfit Kappa bookend FTSE 100	Feb. 07	AN
RedX Pharma to Sell Kirsten Rat Sarcoma Virus Inhibitor Program to Jazz Pharmaceuticals	Feb. 07	MT
Redx Pharma shares skyrocket on deal to sell inhibitor program	Feb. 07	AN
AIM WINNERS & LOSERS: Verditek falls on cash shell plans	Feb. 07	AN

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Jazz Pharmaceuticals plc

Equities

JAZZ

IE00B4Q5ZN47

Highlights

Filters